Browsing restrictions can be lifted for a fee.
Caliway Biopharmaceuticals Co.Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. The company was founded in 2012 and is based in New Taipei City, Taiwan.
6919
康霈*
-5.69%
(-0.06)
The most recent financial report for 康霈* (6919) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6919's short-term business performance and financial health. For the latest updates on 6919's earnings releases, visit this page regularly.
According to the latest financial report, 康霈* (6919) reported an Operating Profit of -201.48M with an Operating Margin of -1,501.89% this period, representing a decline of 31.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 康霈* (6919) announced revenue of 13.42M, with a Year-Over-Year growth rate of -42.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 康霈* (6919) held Total Cash and Cash Equivalents of 3B, accounting for 0.32 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 康霈* (6919) did not achieve the “three margins increasing” benchmark, with a gross margin of 69.53%%, operating margin of -1,501.89%%, and net margin of -57.62%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6919's profit trajectory and future growth potential.
According to the past four quarterly reports, 康霈* (6919)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
康霈* (6919)'s Free Cash Flow (FCF) for the period is 2.8B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 143.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.